• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria

Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria

by Adam | Oct 22, 2016

Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria. Scripps Research Institute. Mol Genet Metab. 2007 Aug. [ISPRI prediction of immunogenicity]
Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein

by Adam | Oct 22, 2016

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein Scios Inc, Brown University, Amgen Clinical Immunology (2007). [ISPRI prediction of immunogenicity]
Epitope-Driven TB Vaccine Development: A streamlined approach using immunoinformatics, ELISpot assays, and HLA transgenic mice

Epitope-Driven TB Vaccine Development: A streamlined approach using immunoinformatics, ELISpot assays, and HLA transgenic mice

by Adam | Oct 22, 2016

Current Molecular Medicine, Curr Mol Med. 2007 Jun;7(4):351-68.
Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine

Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine

by Adam | Oct 22, 2016

Vaccine. 2007 Apr 20;25(16):3179-91.
Analysis of ChimeriVax Japanese Encephalitis (JE) Virus envelope for T-cell epitopes and comparison to circulating strain sequences

Analysis of ChimeriVax Japanese Encephalitis (JE) Virus envelope for T-cell epitopes and comparison to circulating strain sequences

by Adam | Oct 22, 2016

Recent Posts

  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

  1. Homepage on Doing Well and Giving Back in December

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.